Quick Answer
NovaBridge Biosciences reported Total Revenue of $632.0 thousand for fiscal year 2023.
NovaBridge Biosciences — Key Financials by Year
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|
| Total Revenue | — | $632.0K +140.7% |
-$1.55M -101.8% |
$88.03M -94.3% |
$1.54B +5042.2% |
$30.00M -44.2% |
| Revenue (ASC 606) | — | — | — | $13.81M -99.1% |
$1.54B +5042.2% |
$30.00M -44.2% |
| Net Income | -$22.23M +89.3% |
-$207.73M +44.0% |
-$371.05M +84.1% |
-$2.33B -595.1% |
$470.92M +132.4% |
-$1.45B -260.4% |
| Diluted EPS | -$0.12 +89.0% |
-$1.09 +44.4% |
-$1.96 +85.3% |
-$13.35 -545.0% |
$3.00 +101.5% |
-$201.19 -226.1% |
| Total Assets | $212.68M -42.4% |
$368.92M -90.9% |
$4.07B -27.3% |
$5.60B -11.6% |
$6.33B +264.5% |
$1.74B -26.9% |
| Cash and Equivalents | $68.26M -76.6% |
$291.51M -15.0% |
$342.92M -90.3% |
$3.52B -26.0% |
$4.76B +318.4% |
$1.14B -28.4% |
| Stockholders Equity | $201.16M -17.1% |
$242.58M -41.9% |
$417.81M -41.6% |
$715.15M -87.3% |
$5.63B +376.6% |
-$2.03B -113.0% |
| R&D Expense | $21.77M +1.5% |
$21.45M -4.9% |
$22.55M -98.1% |
$1.21B +23.2% |
$984.69M +17.2% |
$840.41M +97.3% |
| Operating Income | -$51.43M +28.6% |
-$72.02M -35.7% |
-$53.08M | — | — | — |
| Shares Outstanding | 187.45M +1.0% |
185.61M -2.8% |
190.88M +3.8% |
183.83M +11.5% |
164.89M +1871.5% |
8.36M +0.0% |
- NovaBridge Biosciences reported Total Revenue of $632.0 thousand for fiscal year 2023.
- NovaBridge Biosciences showed an increase of +140.7% in Total Revenue compared to the prior fiscal year.
- NovaBridge Biosciences reported Revenue (ASC 606) of $13.81 million for fiscal year 2021.
- NovaBridge Biosciences showed a decrease of -99.1% in Revenue (ASC 606) compared to the prior fiscal year.
- NovaBridge Biosciences reported Net Income of -$22.23 million for fiscal year 2024.
- NovaBridge Biosciences showed an increase of +89.3% in Net Income compared to the prior fiscal year.
- NovaBridge Biosciences reported Diluted EPS of $0.12 per share (loss) for fiscal year 2024.
- NovaBridge Biosciences showed an increase of +89.0% in Diluted EPS compared to the prior fiscal year.
- NovaBridge Biosciences reported Total Assets of $212.68 million for fiscal year 2024.
- NovaBridge Biosciences showed a decrease of -42.4% in Total Assets compared to the prior fiscal year.
- NovaBridge Biosciences reported Cash and Equivalents of $68.26 million for fiscal year 2024.
- NovaBridge Biosciences showed a decrease of -76.6% in Cash and Equivalents compared to the prior fiscal year.
- NovaBridge Biosciences reported Stockholders Equity of $201.16 million for fiscal year 2024.
- NovaBridge Biosciences showed a decrease of -17.1% in Stockholders Equity compared to the prior fiscal year.
- NovaBridge Biosciences reported R&D Expense of $21.77 million for fiscal year 2024.
- NovaBridge Biosciences showed an increase of +1.5% in R&D Expense compared to the prior fiscal year.
- NovaBridge Biosciences reported Operating Income of -$51.43 million for fiscal year 2024.
- NovaBridge Biosciences showed an increase of +28.6% in Operating Income compared to the prior fiscal year.
- NovaBridge Biosciences reported Shares Outstanding of 187.45 million shares for fiscal year 2024.
- NovaBridge Biosciences showed an increase of +1.0% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: